PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Recruiting

Phase 3

KVD900PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Sponsor:

KalVista Pharmaceuticals, Ltd.

Code:

NCT05511922

Conditions

Hereditary Angioedema

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

KVD900 600 mg

Drug: KVD900 300 mg

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by KalVista Pharmaceuticals, Ltd. on 2025-01-08.